Current markers such as tumor tissue PD-L1 detection, TMB, and MSI-H/dMMR face limitations due to varied detection platforms, tissue acquisition challenges, and difficulties in dynamic monitoring (8, 9, 10). This evidence concerns the gene CD274 and neoplasm.